Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Assets (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Current Assets for 9 consecutive years, with $574.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Current Assets fell 24.3% year-over-year to $574.2 million, compared with a TTM value of $574.2 million through Jun 2025, down 24.3%, and an annual FY2024 reading of $660.9 million, up 140.07% over the prior year.
  • Current Assets was $574.2 million for Q2 2025 at Autolus Therapeutics, down from $615.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $758.6 million in Q2 2024 and bottomed at $259.0 million in Q2 2022.
  • Average Current Assets over 5 years is $458.0 million, with a median of $390.6 million recorded in 2022.
  • The sharpest move saw Current Assets crashed 35.34% in 2023, then skyrocketed 140.07% in 2024.
  • Year by year, Current Assets stood at $347.0 million in 2021, then rose by 22.72% to $425.8 million in 2022, then plummeted by 35.34% to $275.3 million in 2023, then surged by 140.07% to $660.9 million in 2024, then fell by 13.11% to $574.2 million in 2025.
  • Business Quant data shows Current Assets for AUTL at $574.2 million in Q2 2025, $615.8 million in Q1 2025, and $660.9 million in Q4 2024.